Pharma M&A is reshaping global manufacturing networks — but true value isn’t created by assets alone. It’s created by people, behaviours and a shared commitment to quality. Our latest whitepaper explores why quality culture has become a decisive value driver in pharma integrations and outlines practical steps to build a patient-centric, sustainable culture that accelerates performance and protects deal value. Discover how to lead your quality culture by choice — not by chance.
Beyond closing the deal
How quality culture can determine the success of pharma M&A
Key insights
- Quality culture is a strategic value driver, directly influencing supply reliability, regulatory trust, talent retention and financial outcomes.
- Leading regulators now see quality culture as the foundation of reliable quality systems, enabling lower costs, fewer disruptions and greater long‑term value.
- 30% of M&A deals fail to meet financial targets due to cultural misalignment, highlighting why cultural signals should be assessed early in due diligence.
- A shared patient‑centric mindset transforms compliance into true ownership and accountability, aligning decisions across entities and enabling faster, more coherent integration.
- Strong cultural foundations protect reputation and deal value, while reducing the cost of poor quality, which can reach 10–40% of operational costs in pharma manufacturing.
- The paper presents a four-stage model for shaping quality culture: understanding the starting point, aligning leadership, co-creating future quality culture, and sustaining it through structured reinforcements.
- The paper includes real-world integration examples from leadership workshops to gamified shopfloor learnings.
Contact us
Luca Borrelli
Partner, Swiss Health Industries Deals Leader, PwC Switzerland
